ToxSci Advance Access originally published online on February 16, 2005
Toxicological Sciences 2005 85(1):476-490; doi:10.1093/toxsci/kfi119
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Development of a Physiologically Based Pharmacokinetic Model for Ethylene Glycol and Its Metabolite, Glycolic Acid, in Rats and Humans
* Battelle Pacific Northwest Division, Richland, Washington 99352; The Dow Chemical Company, Midland, Michigan 48674
Received October 26, 2004; accepted February 12, 2005
An extensive database on the toxicity and modes of action of ethylene glycol (EG) has been developed over the past several decades. Although renal toxicity has long been recognized as a potential outcome, in recent years developmental toxicity, an effect observed only in rats and mice, has become the subject of extensive research and regulatory reviews to establish guidelines for human exposures. The developmental toxicity of EG has been attributed to the intermediate metabolite, glycolic acid (GA), which can become a major metabolite when EG is administered to rats and mice at high doses and dose rates. Therefore, a physiologically based pharmacokinetic (PBPK) model was developed to integrate the extensive mode of action and pharmacokinetic data on EG and GA for use in developmental risk assessments. The resulting PBPK model includes inhalation, oral, dermal, intravenous, and subcutaneous routes of administration. Metabolism of EG and GA were described in the liver with elimination via the kidneys. Metabolic rate constants and partition coefficients for EG and GA were estimated from in vitro studies. Other biochemical constants were optimized from appropriate in vivo pharmacokinetic studies. Several controlled rat and human metabolism studies were used to validate the resulting PBPK model. When internal dose surrogates were compared in rats and humans over a broad range of exposures, it was concluded that humans are unlikely to achieve blood levels of GA that have been associated with developmental toxicity in rats following occupational or environmental exposures.
Key Words: ethylene glycol; glycolic acid; PBPK modeling.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. A. Knudsen, Y. Cheng, R. K. Kuester, M. J. Hooth, and I. G. Sipes Effects of Dose and Route on the Disposition and Kinetics of 1-Butyl-1-methylpyrrolidinium Chloride in Male F-344 Rats Drug Metab. Dispos., November 1, 2009; 37(11): 2171 - 2177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. G. Sipes, G. A. Knudsen, and R. K. Kuester The Effects of Dose and Route on the Toxicokinetics and Disposition of 1-Butyl-3-methylimidazolium Chloride in Male F-344 Rats and Female B6C3F1 Mice Drug Metab. Dispos., February 1, 2008; 36(2): 284 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Marty, J. Y. Domoradzki, S. C. Hansen, C. Timchalk, M. J. Bartels, and J. L. Mattsson The Effect of Route, Vehicle, and Divided Doses on the Pharmacokinetics of Chlorpyrifos and Its Metabolite Trichloropyridinol in Neonatal Sprague-Dawley Rats Toxicol. Sci., December 1, 2007; 100(2): 360 - 373. [Abstract] [Full Text] [PDF]
|
|